newsfilter
← Latest News
GlobeNewswire·

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary